20.500.12556/DiRROS-8713 Intratekalna aplikacija trastuzumaba in rituksimaba Intrathecal Administration of trastuzumab and rituximab Neoplastični meningitis je resen zaplet maligne bolezni. Kljub majhni incidenci njegova pogostost narašča, domnevno zaradi daljšega preživetja bolnikov in izboljšane diagnostike. Neoplastični meningitis se zdravi s sistemsko in intratekalno kemoterapijo ter z obsevanjem osrednjega živčevja. Trastuzumab in rituksimab sta monoklonski protitelesi, ki sta ob intravenskih aplikacijah pomembno izboljšali preživetje bolnikov z rakom dojk in Nehodgkinovim limfomom. Manj sta učinkoviti pri zdravljenju neoplastičnega meningitisa, saj zaradi velikosti ne prehajata krvno-možganske pregrade. Novejše raziskave preučujejo tudi možnost intratekalne aplikacije monoklonskih protiteles. Neoplastic meningitis is a serious complication of malignant disease. In spite of low incidence, its frequency is increasing. This is believed to be due to better cancer patient survival and improved diagnostic procedures. Treatment of neoplastic meningitis usually consists of systemic and intrathecal therapy along with radiotherapy of central nervous system. Trastuzumab and rituximab are monoclonal antibodies that significantly improved the outcome of breast cancer and nonHodgkin lymphoma patients. While the two monoclonal antibodies are effective agents for their respective disease states, their efficacy is poor in the treatment of neoplastic meningitis as they are unable to cross the blood-brain barrier. This is a review of evidence for the potential use of intrathecal trastuzumab and rituximab. onkologija neoplastični meningitis zdravljenje true false true Slovenski jezik Angleški jezik by Authors Neznano 2018-08-31 13:28:47 2018-08-31 13:28:47 2022-08-16 10:15:51 0000-00-00 00:00:00 2011 0 0 str. 39-42 št. 1 Letn. 15 jun. 2011 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616.831-006.6-08 1408-1741 URN:NBN:SI:doc-64L1Y4F1 1132411 65324032 RAZ_Rozman_Samo_i2011.pdf RAZ_Rozman_Samo_i2011.pdf 1 88AA47A03FD2555F49B5E8D9D1287BD7 df3b7e9c37a9afff49f00da0647a74aeec164301c161e1e78c10f91349408325 59485a88-17b5-11ed-b6b8-001a4af901a5 20.500.12556/dirros/63fd768b-0fc4-4175-830b-20715cce7263 https://dirros.openscience.si/Dokument.php?lang=slv&id=10494 Onkološki inštitut Ljubljana Onkologija : strokovni časopis za zdravnike 0 0 0